- Home
- CMMB vs GDTC Comparison
CMMB vs GDTC Comparison
Compare CMMB & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- GDTC
- Stock Information
- Founded
- CMMB 2004
- GDTC 2018
- Country
- CMMB Israel
- GDTC Singapore
- Employees
- CMMB N/A
- GDTC N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- GDTC Health Care
- Exchange
- CMMB Nasdaq
- GDTC Nasdaq
- Market Cap
- CMMB 27.0M
- GDTC 25.7M
- IPO Year
- CMMB N/A
- GDTC 2023
- Fundamental
- Price
- CMMB $1.65
- GDTC $2.26
- Analyst Decision
- CMMB Strong Buy
- GDTC Buy
- Analyst Count
- CMMB 3
- GDTC 1
- Target Price
- CMMB $7.33
- GDTC $5.00
- AVG Volume (30 Days)
- CMMB 106.7K
- GDTC 11.1K
- Earning Date
- CMMB 11-14-2024
- GDTC 01-01-0001
- Dividend Yield
- CMMB N/A
- GDTC N/A
- EPS Growth
- CMMB N/A
- GDTC N/A
- EPS
- CMMB N/A
- GDTC N/A
- Revenue
- CMMB N/A
- GDTC $330,254.00
- Revenue This Year
- CMMB N/A
- GDTC $14.71
- Revenue Next Year
- CMMB N/A
- GDTC N/A
- P/E Ratio
- CMMB N/A
- GDTC N/A
- Revenue Growth
- CMMB N/A
- GDTC N/A
- 52 Week Low
- CMMB $0.42
- GDTC $1.20
- 52 Week High
- CMMB $2.55
- GDTC $5.50
- Technical
- Relative Strength Index (RSI)
- CMMB 55.47
- GDTC 51.08
- Support Level
- CMMB $1.55
- GDTC $1.88
- Resistance Level
- CMMB $1.73
- GDTC $2.35
- Average True Range (ATR)
- CMMB 0.16
- GDTC 0.36
- MACD
- CMMB 0.01
- GDTC -0.04
- Stochastic Oscillator
- CMMB 52.83
- GDTC 42.95
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.